USFDA issues warning letter to Intas Pharma for Sanand plant

The USFDA inspected the manufacturing facility from November 22 to December 2, 2022. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/osf1lAr
via gqrds

Comments

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

Women in India Report Higher Sleep Deprivation Than Men

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018